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Abstract: Diabetic retinopathy (DR) is the most common complication of diabetes mellitus in 
the eye. Although the clinical treatment for DR has already developed to a relative high level, 
there are still many urgent problems that need to be investigated in clinical and basic science. 
Currently, many in vivo animal models and in vitro culture systems have been applied to solve 
these problems. Many approaches have also been used to establish different DR models. How-
ever, till now, there has not been a single study model that can clearly and exactly mimic the 
developmental process of the human DR. Choosing the suitable model is important, not only 
for achieving our research goals smoothly, but also, to better match with different experimental 
proposals in the study. In this review, key problems for consideration in choosing study mod-
els of DR are discussed. These problems relate to clinical relevance, different approaches for 
establishing models, and choice of different species of animals as well as of the specific in vitro 
culture systems. Attending to these considerations will deepen the understanding on current 
study models and optimize the experimental design for the final goal of preventing DR.
Keywords: animal model, in vitro culture, ex vivo culture, neurovascular dysfunction
Introduction
The worldwide incidence of diabetes is rising quickly. Studies have shown that after 
10 years of diabetes, nearly 50% of type 2 and 70% of type 1 diabetic patients will 
develop diabetic retinopathy (DR).1 As a leading cause of blindness in eye diseases, DR 
drives much attention, on the part of clinical and basic researchers, to the investigation of 
its mechanism and prevention. However, the pathogenesis of DR is complicated, so vali-
dated study models are needed to deepen our understanding of the disease mechanisms 
and for trying new approaches for early screening and therapeutic intervention.
DR is a common clinical condition. As to study models for DR, there are several 
different species of animal models, from tiny zebrafish to monkeys, and in vitro culture 
systems for retinal blood vessel assay, using human or nonhuman tissues. All of these 
models are aimed at mimicking the clinical course of DR, while each has its limita-
tion in matching the full features of the human disease. Previously, there have been 
some reviews describing animal models of DR in great detail.2–6 In addition, there are 
other reviews focusing on angiogenesis models in vivo7 and in vitro.8 However, when 
a researcher is faced with choosing the study model for different purposes, there are 
many key problems to consider in advance.
In this review, a summary of the most common and important problems for 
consideration on the selection of appropriate study models of DR is provided. The 
features and challenges of clinical DR that should be considered in preclinical studies 
are discussed first. Then, the current research focuses in clinical and basic science are 
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summarized, for researchers to consider and compare with 
their own experimental goals. Finally, the popular modeling 
approaches in common animal species, together with their 
advantages and limitations, are summarized. These consider-
ations will help researchers to select the appropriate candidate 
when facing multiple choices of study models.
Clinical considerations
Characteristics of human DR
Clinically, DR is mainly classified in two groups, nonpro-
liferative DR (NPDR) and proliferative DR (PDR). PDR 
is judged by the presence of retinal neovascularization,9 
which is usually confirmed with fluorescence fundus 
angiography imaging. PDR is the more advanced stage 
of DR. In PDR, proliferating neovasculature contributes 
to severe complications, eg, vitreous hemorrhage, retinal 
scars, and tractional retinal detachment, all of which often 
need vitreoretinal surgery. However, the endpoint of PDR is 
variable, and irreversible vision loss is attributed to retinal 
structure damage and layer thinning. Thus, the Early Treat-
ment of Diabetes Retinopathy Study (ETDRS) has staged 
NPDR with mild, moderate, and severe grades, aimed to 
screen risk factors and to detect the earlier stages of DR 
for nonsurgical treatment, eg, retinal photocoagulation or 
antiangiogenic therapy.10,11
Histologically, retinal vascular lesions are considered to 
be the hallmark and the grading criterion of DR. The first 
visible alteration in retinal vasculature is the formation of 
microaneurysms. The further changes are intraretinal focal 
hemorrhage, venous beading, and intraretinal microvascular 
abnormalities (IRMAs) showing with microvascular torsion 
and regional capillary nonperfusion on fluorescence fundus 
angiography imaging. IRMA is associated with “cotton 
wool” spots observed with funduscopy, which are focal 
infarcts of nerve fibers in essence. Following the progression 
of vascular damage, diabetic macular edema appears, which 
is one of the major causes of vision loss in DR, linking with 
lesions at the blood–retinal barrier.12,13
Clinical challenges
A current clinical challenge for consideration in diagnosis and 
prevention is the screening for risk factors that contribute to 
retinal vascular abnormality, for eg, studies of ocular blood 
flow;14,15 biomarkers detected in body fluids, like advanced 
glycation end products (AGEs); interleukins; and tumor 
necrosis factor-α (TNF-α).16,17
As to nonsurgical therapeutic investigations, the 
focus has been on treating diabetic macular edema and 
  antiangiogenesis, and on vascular cell protection to inhibit 
neovascularization, for eg, with vascular endothelial growth 
factor (VEGF) inhibitor18 or other potential ocular-delivered 
drugs.19–22 Recently, anti-VEGF has become one of most 
important discoveries to treat neovascularization clinically. 
However, limitations to anti-VEGF therapies also exist, eg, 
resistance, systemic side effects with local use, and non-
VEGF-related vascular proliferative mechanisms.18–22 Indeed, 
other than VEGF, more and more potentially angiogenic fac-
tors have been discovered, such as insulin-like growth factor 
1 (IGF-1),23 platelet-derived growth factor B (PDGF-B), 
erythropoietin (EPO), angiopoietin 2,24 interleukin 8 (IL-8), 
etc.25 Antioxidants, eg, alpha-lipoic acid (ALA), are other 
potential drugs that prevent micro- and macrovascular dam-
age, by normalizing pathways downstream of mitochondrial 
overproduction of reactive oxygen species, and preserve 
pericyte coverage of retinal capillaries.26,27
As to surgical aspects, treatment advances are largely 
dependent on development of new instruments for the goal 
of perfecting results of vitreoretinal surgery. However, when 
DR is advanced to the proliferative stage, surgical effect 
is limited to the severe damage of retinal neurovascular 
structure.28,29
Thus, more and more preclinical trials need to use dif-
ferent in vivo animal models or in vitro vascular assays to 
understand the mechanisms and to find potential treatment 
to prevent human DR.
Choices of study model in DR
Principle of choice: Research goal is the 
basic consideration
Understanding of the mechanism of DR is complicated by 
the complexity of the retinal structure. The retina contains 
multiple cell components and structure, and when exposed 
to the stress of hyperglycemia, not only blood vessels but 
also, retinal neurons and glial cells will all be challenged by 
the insult. The concept of the neurovascular unit is a kind of 
simplified understanding of the crosstalk between the retinal 
blood vessel and other cells around it.30 From the view of 
a neurovascular hypothesis in DR, conditions of hypergly-
cemia induce vascular damage, thereafter destroying the 
microenvironment and the crosstalk between endothelial 
cells/pericytes and neurons, endothelial cells/pericytes and 
retinal glial cells, as well as neurons and glial cells, finally 
leading to vascular proliferation, glial proliferation, and 
neural degeneration (Figure 1).
Previously, the focus was on establishing various ani-
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  investigating morphological damage to the retinal vasculature 
and comparing this to clinical features found in human DR. 
Studies have shown that one of the earliest histological 
changes of DR is thickening of the capillary basement mem-
brane.31 Dysfunction of endothelial cells and pericytes, and 
thereafter cell loss, are also early phenomena, which could 
be responsible for the acellular capillary formation.4 It is 
believed that the formation of microaneurysms, the hallmark 
alteration of human DR, are attributed to the loss of peri-
cytes.32 Cotton wool spots are linked with focal IRMAs.33
Therefore, we summarized the current research areas 
and categorized them with respect to the different stages of 
development of DR and according to their different goals. At 
different stages of NPDR and PDR, there have been different 
points of focus, for eg, in NPDR, the blood vessel-related 
research focuses on early biomarkers to detect vascular 
dysfunction,34 the mechanisms for how hyperglycemia 
induces vascular damage,35 and potential treatment to protect 
endothelial cells or pericytes from dysfunction or loss.22 
Neuron-related research has focused on early detection of 
neural degeneration by electrophysiological methods,36,37 and 
neuroprotection.38,39 Glial cell-related research focuses on the 
response of retinal astrocytes and Müller cells.39 Microen-
vironment damage–related research directions include 
cytokines and the mechanisms of inflammation, as well as 
immune-associated mechanisms, etc.40 As to preventing 
PDR, the current research goals relate to potential therapies 
for inhibiting or treating the complications of neovasculariza-
tion, eg, anti-VEGF, which was mentioned above. Thus, after 
clarifying the goal of investigation and the related stage in 
DR, researchers can pay attention to the choices for different 
approaches and study models.
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Figure 1 Neurovascular hypothesis for the pathogenesis of diabetic retinopathy.
Abbreviations: BM, basement membrane; BRB, blood–retinal barrier; NPDR, nonproliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy.Drug Design, Development and Therapy 2014:8 submit your manuscript | www.dovepress.com
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Different choices to establish study model 
of DR
Currently, in the establishment of animal models for DR, 
there are mainly three approaches: 1) inducing experimental 
hyperglycemia, 2) using animals with spontaneous diabetes 
mellitus, and 3) inducing retinal angiogenesis without dia-
betes mellitus.
As to the approach of experimental hyperglycemia induc-
tion, this mainly includes: a) pharmacological methods, for 
eg, intraperitoneal injection of streptozotocin (STZ)41–45 or 
alloxan;46 b) diet methods, such as feeding a high-galactose 
diet;46 and c) surgical method, for eg, Pancreatectomy.47
a)  Regarding induction of pharmacological hyperglyce-
mia, intraperitoneal injection using STZ is the classic 
and most popular approach to establish diabetic animal 
models. The mechanism is that STZ can kill pancreatic 
β cells by its toxicity. Following the hyperglycemia, 
the animal will develop DR. Compared with the other 
methods listed above, STZ injection is time-saving and 
efficient and has been used widely in rodents and large 
animals, for eg, rabbits, cats, dogs, pigs, and monkeys. 
The standard modeling protocol that has been established 
in mice was suggested by the Animal Models of Diabetic 
Complications Consortium.48 It has been reported that the 
STZ-induced model could demonstrate NPDR, however, 
rarely forming microaneurysms.49 In addition, only a few 
studies reported the formation of focal neovasculariza-
tion.50 Alloxan is another drug used to induce hyperglyce-
mia. However, compared with STZ, the alloxan-induced 
model has needed longer time to demonstrate a milder 
level of pathological change of DR – reportedly 3 months 
in mice46 and 12 months in rats.51
b)  The high galactose-diet feeding method can be used in 
rodents and other large animals. Compared with the STZ 
method, it is time-consuming. However, it is suitable for 
zebrafish, by just directly elevating the concentration of 
glucose in the fishpond.52
c)  Surgical methods, like pancreatectomy, can be used 
in large animals, such as cats,47 pigs,53 and monkeys.54 
However, it is also time-consuming, for eg, in one 
report using cats, although hyperglycemia was induced 
quickly, within 1–2 weeks after the surgery, DR and 
formation of microaneurysms was observed only after 
around 5 years.47 Generally, experimental hyperglycemia-
inducted methods can be applied in wide types of animals, 
without obvious species limitation.
As to the approach of using spontaneously diabetic animals 
for study of DR, this mainly refers to use of genetic technology 
to create animals that develop hyperglycemia and diabetes 
mellitus spontaneously, followed by the development of the 
pathological changes of DR. The spontaneous DR model 
has been established using mice, rats, and zebrafish. The DR 
animal created under this method shares the advantage of 
consistent phenotypes and high successful rate of induction. 
However, higher cost and genetic technology are needed. In 
addition, compared with experimentally induced-DR methods, 
spontaneous diabetic animals need a longer period to demon-
strate DR. There are a relatively small number of animals with 
special strains that can develop diabetes spontaneously, but 
this has been reported in rats and monkeys (Table 2). Similarly, 
these animals with intraspecies variation also need a longer 
period to demonstrate DR, while the phenotypic variation is 
larger than for genetically mutated animals.
As to the method of retinal angiogenesis-induction, this 
refers to inducing retinal blood vessel proliferation without 
elevation of the blood glucose. The popular methods include 
oxygen-induced retinopathy and VEGF ocular delivery. 
Currently, the oxygen-induced retinopathy method is stan-
dardized and popularly applied in mice55 and rats,56 while the 
method of VEGF ocular delivery is more suitable for larger 
animals, for eg, rabbit and monkey.57 Technically, these are 
not specific DR models, since they share phenotypes with 
other retinal neovascular diseases, such as retinopathy of pre-
maturity, retinal vein occlusion, and retinal artery occlusion. 
However, from the view of pathogenesis, neovascularization 
is the same key pathogenesis in PDR. In addition, the angio-
genic method can induce advanced vascular proliferation to 
mimic PDR, while the hyperglycemia-induced models mostly 
mimic NPDR. We summarized the rationale, advantages, and 
limitations for each popular modeling approach currently 
used in DR in Table 1.
Animal choices in vivo and cell culture 
choices in vitro
Genetically, mouse and zebrafish have the greatest poten-
tial as in vivo animal models of DR for the investigation 
of mechanisms and preclinical drug screening. They have 
advantages such as similar gene background to humans and 
ease of manipulation by the current genetic technology. In 
addition, the small size of animal is also easy to handle and 
house, and the short lifespan and large breeding rate can 
shorten the experimental period. These types of animals 
are inexpensive themselves, although gene modification 
enhances their cost. However, with the maturation of gene 
technology, more and more commercial gene-modified 
animals have already been made available for purchase for Drug Design, Development and Therapy 2014:8 submit your manuscript | www.dovepress.com
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achieving different experimental goals with a not very high 
price. Detailed description of the characteristics of these 
genetic animals is beyond the purpose in this review; we 
listed the related references in Table 2. In addition, double-
gene transgenic or fluorescent gene-added animals extend our 
understanding and deepen our investigation of the molecular 
nature of human diseases. These are unique advantages when 
compared with other animal models.58–62
Experimentally, mice and rats are still the most popular 
models of DR, not only because of the advantages mentioned 
above, but also since there have been many standardized 
protocols of modeling approaches available for reference 
to researchers, such as the STZ-injection model, oxygen-
induced retinopathy model, and genetic model. In addi-
tion, rodents are suitable for the vast majority of detection 
reagents used in the laboratory. Monkey models share the 
most similar features of human DR compared with other 
animal models, which could be applied in research fields 
like live imaging examinations, diagnosing biomarker 
screening, and medical or surgical therapeutic trials; how-
ever, the approaches for monkeys are far from mature when 
compared with those for rodents. In addition, the large size, 
long lifespan, and inevitable ethical requirements have 
largely limited their applications. Other large animals, like 
cats and dogs, have large-sized eye balls, which are more 
convenient for handling than rodent eyes. However, their 
gene backgrounds are far from human, the number of suit-
able experimental reagents is far less than for rodents, and 
their large size needs more housing space, which all limited 
their usage as the choice of animal models for DR. However, 
compared with all the above species of animals, the zebrafish 
has its own advantages as a potential DR model, for eg, the 
experimental methods of STZ injection,63 high-glucose diet 
feeding,52 and hypoxia-induced retinopathy (HIR)64 are all 
convenient to perform in zebrafish, and the zebrafish with the 
gene vhl–/– mutation is a spontaneous VEGF-overexpressing 
animal model, which makes it suitable to mimic the develop-
ment of PDR62. However, the less similar retinal vascular 
structure to human, difficult handling, because of tiny size, 
and lack of reagents for molecular studies still limit its 
usage.
Compared with the in vivo animal model, in vitro culture 
systems can be used as experimental models of retinal angio-
genesis. Since pathological angiogenesis of the retina is the 
key cause of progression in PDR, the retinal angiogenesis 
assay is suitable for screening novel antiangiogenic drugs 
before testing in vivo animals and in patients clinically. 
In this area, study about various VEGF blockers is the most 
important direction in recent years. Several generations have 
been updated, and some of them have been applied clinically 
to patients, for eg, pegaptanib, ranibizumab, aflibercept, and 
bevacizumab.65,66
Currently, there are two main kinds of in vitro culture 
proposals. Traditional in vitro cell culture uses isolated 
endothelial cells or pericytes, in particular, to maximally 
mimic the human angiogenic process; human-source 
endothelial cells and pericytes can be used more conveniently 
than in vivo study. Moreover, retina-derived endothelial 
cells can be applied67 for the search of specific inhibitors of 
retinal neovascularization. However, the traditional in vitro 
culture has its weakness since without the microenvironment 
of retina, isolated cells may possibly lose their responses 
to angiogenic molecules. Thus, another culture proposal 
has been created, which is the ex vivo retinal model. The 
ex vivo model is established with retinal culture. In PDR, 
isolating the retina from the in vivo DR model for culture 
in vitro can be useful for studying the role of proangiogenic 
factors or antiangiogenic factors in the development of reti-
nal neovascularization.23,25,68,69 We summarized the popular 
methods applied in common modeling animals and culture 
systems in Table 2.
Conclusion
The experimental model is the link between basic and clinical 
research. It deepens our understanding of the mechanisms and 
supports us in discovering novel therapeutic interventions to 
prevent the progression of DR. However, each DR model has 
its own advantages and limitations. Careful consideration in 
choosing the model helps us achieve the research goal with 
high efficiency. The preclinical modeling experiments are 
ultimately beneficial to clinical patients.
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